Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
about
Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthaseA gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in womenTriglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementEvidence of lifestyle modification in the management of hypercholesterolemia.Update on guidelines for management of hypercholesterolemia.Lower serum triglyceride level is a risk factor for in-hospital and late major adverse events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention- a cohort study.High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trialStatin therapy in patients with acute coronary syndrome: low-density lipoprotein cholesterol goal attainment and effect of statin potencyThe effects of different doses of atorvastatin on serum lipid profile, glycemic control, and liver enzymes in patients with ischemic cerebrovascular accident.Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thicknessInfluence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled studyLipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden.Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial.Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammationIntensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials.Impact of adherence to statins on coronary artery disease in primary prevention.Effects of atorvastatin on serum lipids, serum inflammation and plaque morphology in patients with stable atherosclerotic plaquesRationale, design, and implementation of aggressive risk factor management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial.Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm.Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imagingCoping with new challenges in acute coronary syndromes.Intensive statin therapy for treating acute coronary syndromes.Role of statins in coronary artery diseaseStatin diabetogenicity: guidance for cliniciansImportance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.The cholesterol paradox in heart failure.Prompt impact of first prospective statin mega-trials on postoperative lipid management of CABG patients: a 20-year follow-up in a single hospital.Pleiotropic effects and cholesterol-lowering therapy.Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol.Pleiotropic vasoprotective effects of statins: the chicken or the egg?Reduction in early stroke risk in carotid stenosis with transient ischemic attack associated with statin treatmentIntensive statin therapy in coronary artery disease: is lower cholesterol better and safe?Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies.Statins in acute coronary syndrome: very early initiation and benefits.Current statin usage for patients with acute coronary syndrome undergoing percutaneous coronary intervention: multicenter survey in Korea.A review of statin use in patients with acute coronary syndrome in Western and Japanese populations.Anti-inflammatory strategies for plaque stabilization after acute coronary syndromes.Return to work after coronary artery bypass surgery. A 10-year follow-up study.Effect of previous statin therapy in patients with acute coronary syndrome and percutaneous coronary intervention
P2860
Q24630160-11248CCD-77B5-489A-B1F4-2B5100C0E053Q33565388-172BC935-B9A2-4E54-8998-DE12C3C1FC53Q33634188-F81FA9FA-1565-485A-91B3-2B1C498A5665Q34181381-F26C2994-D53F-4E75-B400-317A7E1E5E60Q34301108-C7977E61-67F0-4CA6-9DF5-BC9C4535034FQ34314183-16D2C5EA-53D6-440F-83E0-F8EC9B20DBCCQ34340167-FC886807-F6B3-44E8-A702-FC4B848D1030Q34763977-4D93A2B2-CCDC-4839-81D5-6667A4591D00Q35043492-54260CC5-F322-4C9F-8CCE-FA55287E5606Q35160603-F10346FB-1857-4C8F-BBD1-572DF7DB9C34Q35196130-35DBB936-530D-4DEF-918F-69A9275C6544Q35617640-7C4594CF-EB29-4425-B432-E0288A93AAEDQ35901322-A878AE64-AE29-4BC6-A716-4C2D2B6C3E54Q35929446-BF2E02E5-E5B4-4A78-BF68-1CAB70835D63Q35964485-1547E316-7028-4B25-818B-28A9226F1BA5Q36014039-851D0B99-5378-4962-9006-6EC752E01277Q36024456-9A518F20-5E68-4133-8199-835378A41FE8Q36386629-CAACEE8F-2A4E-4068-A447-D4E9958096D1Q36405076-36579B9D-CC17-419D-9EC7-5DBE288E719EQ36519924-67F1959A-67E5-4FAF-94DC-EFCB9F2D59FBQ36537985-4E32EC25-766E-4785-8ADE-E7056134F28CQ36575461-D85E8128-969E-46E4-988A-4C5F4B251487Q36600272-00114545-3B58-4FC9-A32F-1F84FFCCA269Q36837567-1DAB8DA3-1553-49A3-81C8-0A97C1041A28Q36888713-E6209640-9EAA-4736-9938-0B70399F8B93Q37016141-E94573A0-8447-4AED-A210-DF04DC298ED4Q37018475-42C39B4F-3339-4C70-967B-B6ADFDEC1F3EQ37129507-3A499E80-E9F9-457F-AE34-67CF0205DB36Q37199617-9634CF48-6BAE-4F19-B503-E5B9F52FDCECQ37399844-71730A92-8077-4649-A49E-607843502EB4Q37403235-089B1B68-2492-41BE-934F-90ED3576F947Q37411870-6877B843-13D8-4ED1-BFCD-8D28FDDEC3DDQ37445854-2700166D-3706-4997-A0C1-2FF1DA507876Q37659873-B92FB0B7-D05B-475B-BB70-7484D155C7B1Q38025837-1BA77897-8286-477E-A2CA-90DA2D171870Q38028866-C059537F-B29B-448B-88A0-690F7FA554C7Q38097397-8DD8B65E-3839-438B-AF6B-54DE4C4BF22DQ38103488-62AB9A04-B474-4ADF-B08D-18D39B22E7B8Q38424266-AA5401D4-7897-43EC-9126-E7A509F1E752Q38437548-31E7AA39-6CE7-477A-B1D1-5DF306E282E6
P2860
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Early and late benefits of hig ...... om the PROVE IT-TIMI 22 trial.
@ast
Early and late benefits of hig ...... om the PROVE IT-TIMI 22 trial.
@en
Early and late benefits of hig ...... om the PROVE IT-TIMI 22 trial.
@nl
type
label
Early and late benefits of hig ...... om the PROVE IT-TIMI 22 trial.
@ast
Early and late benefits of hig ...... om the PROVE IT-TIMI 22 trial.
@en
Early and late benefits of hig ...... om the PROVE IT-TIMI 22 trial.
@nl
prefLabel
Early and late benefits of hig ...... om the PROVE IT-TIMI 22 trial.
@ast
Early and late benefits of hig ...... om the PROVE IT-TIMI 22 trial.
@en
Early and late benefits of hig ...... om the PROVE IT-TIMI 22 trial.
@nl
P2093
P1476
Early and late benefits of hig ...... om the PROVE IT-TIMI 22 trial.
@en
P2093
Andrew M Tonkin
Carolyn H McCabe
Christopher P Cannon
Frank M Sacks
Graham Jackson
Kausik K Ray
PROVE IT-TIMI 22 Investigators
Richard Cairns
P304
P356
10.1016/J.JACC.2005.03.077
P407
P577
2005-10-01T00:00:00Z